Use of polysaccharide hemostatic agent (<scp>HaemoCer™</scp>) in breast cancer surgery to reduce postoperative complications: A randomised controlled trial
Use of polysaccharide hemostatic agent (<scp>HaemoCer™</scp>) in breast cancer surgery to reduce postoperative complications: A randomised controlled trial is a paper indexed in PICO Portal from OpenAlex.
How many citations does Use of polysaccharide hemostatic agent (<scp>HaemoCer™</scp>) in breast cancer surgery to reduce postoperative complications: A randomised controlled trial have?
Use of polysaccharide hemostatic agent (<scp>HaemoCer™</scp>) in breast cancer surgery to reduce postoperative complications: A randomised controlled trial has 11 citations in the OpenAlex counts PICO Portal stores.
When was Use of polysaccharide hemostatic agent (<scp>HaemoCer™</scp>) in breast cancer surgery to reduce postoperative complications: A randomised controlled trial published?
Use of polysaccharide hemostatic agent (<scp>HaemoCer™</scp>) in breast cancer surgery to reduce postoperative complications: A randomised controlled trial has 2022 year in the PICO Portal index.
What is the open-access status of Use of polysaccharide hemostatic agent (<scp>HaemoCer™</scp>) in breast cancer surgery to reduce postoperative complications: A randomised controlled trial?
Use of polysaccharide hemostatic agent (<scp>HaemoCer™</scp>) in breast cancer surgery to reduce postoperative complications: A randomised controlled trial has gold oa status in the PICO Portal index.
What is the DOI of Use of polysaccharide hemostatic agent (<scp>HaemoCer™</scp>) in breast cancer surgery to reduce postoperative complications: A randomised controlled trial?
The DOI for Use of polysaccharide hemostatic agent (<scp>HaemoCer™</scp>) in breast cancer surgery to reduce postoperative complications: A randomised controlled trial is on the source record.
What is the PMID of Use of polysaccharide hemostatic agent (<scp>HaemoCer™</scp>) in breast cancer surgery to reduce postoperative complications: A randomised controlled trial?
The PMID for Use of polysaccharide hemostatic agent (<scp>HaemoCer™</scp>) in breast cancer surgery to reduce postoperative complications: A randomised controlled trial is on the source record.
What is the OpenAlex record for Use of polysaccharide hemostatic agent (<scp>HaemoCer™</scp>) in breast cancer surgery to reduce postoperative complications: A randomised controlled trial?
The OpenAlex for Use of polysaccharide hemostatic agent (<scp>HaemoCer™</scp>) in breast cancer surgery to reduce postoperative complications: A randomised controlled trial is on the source record.